Literature DB >> 2901885

Depressive syndromes in the year following onset of a first schizophrenic illness*.

A House1, J Bostock, J Cooper.   

Abstract

A complete, unselected series of 68 patients who were seen during their first episode of an undoubtedly schizophrenic illness, and followed up one year later (for 56 patients) is described clinically. Depressive symptoms were common at onset, and 22% of patients could have been considered cases of depression from these symptoms alone. At follow-up, depressive symptoms had reduced in prevalence and only 7% of subjects were depressed cases. Only two cases of depression at follow-up had not been cases at onset. These changes could not be attributed to the use of antidepressants or ECT. Depressive syndromes could be distinguished from akinesia and the negative syndromes. The findings indicate that depression cannot be attributed solely to the administration of neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2901885     DOI: 10.1192/bjp.151.6.773

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

Review 1.  Postpsychotic depression in schizophrenia patients.

Authors:  Christian G Kohler; Elise A Lallart
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

2.  Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Düsseldorf, Göttingen, Munich.

Authors:  B Bandelow; P Müller; W Gaebel; W Köpcke; M Linden; F Müller-Spahn; A Pietzcker; F M Reischies; J Tegeler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

Review 3.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

4.  The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis.

Authors:  Jojanneke Bruins; Frederike Jörg; Richard Bruggeman; Cees Slooff; Eva Corpeleijn; Marieke Pijnenborg
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.